Cover Image
市場調查報告書

Actelion Ltd:開發中產品分析

Actelion Ltd - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 207924
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
Actelion Ltd:開發中產品分析 Actelion Ltd - Product Pipeline Review - 2016
出版日期: 2016年03月30日 內容資訊: 英文 74 Pages
簡介

Actelion Ltd.從事於有助於解決許多未滿足需求的創新治療藥之新創、開發、銷售。此外還有主導內皮素受體拮抗劑(ERA)的開發這樣的實際成果在。該公司的主要產品包含了Tracleer(肺動脈高血壓治療藥)和Ventavis(iloprost,吸用式的前列腺素合成劑),Veletri(注射式epoprostenol),Zavesca(miglustat,低分子量抑制劑)等。

本報告提供瑞士的生物醫藥品企業──Actelion Ltd(Actelion)的醫藥品研究開發進展相關分析,提供該公司的產品平台結構,及臨床實驗的整體進展,主要開發中產品的簡介與開發情形,以及該公司簡介及最新趨勢等調查。

目錄

Actelion Ltd.:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台·檢討

  • 各開發階段的開發中產品
  • 開發中產品:單劑治療藥
  • 開發中產品:合作夥伴產品
    • 合作夥伴產品/並用治療模式

開發中產品的概要

  • 後期階段的開發中產品
    • 登記前產品/並用治療模式
    • PhaseⅢ產品/並用治療模式
  • 臨床實驗階段的開發中產品
    • PhaseⅡ產品/並用治療模式
    • PhaseⅠ產品/並用治療模式
  • 初期階段的開發中產品
    • 臨床實驗前產品/並用治療模式
    • 藥物研發階段的產品/並用治療模式

藥物簡介

  • mashitentan
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展
  • bosentan
  • cadazolid
  • selexipag
  • ACT-280778
  • ponesimod
  • ACT-246475
  • ACT-281959
  • ACT-389949
  • ACT-434964
  • ACT-462206
  • 氣喘·過敏症用CRTH2受體拮抗劑
  • lucerastat
  • Orexin Receptor Antagonist for Insomnia
  • S1P1 Receptor Agonist for Immunological Disorders
  • 心血管疾病用小分子
  • 免疫力缺乏症用小分子
  • 瘧疾用小分子
  • Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Bacterial Infection
  • Small Molecule to Inhibit DNA Ligase for Staphylococcal Infections
  • 化合物-49c
  • Dual Orexin Receptor Antagonist for Insomnia
  • 癌症用小分子

開發平台分析

  • 標的別
  • 各投藥法
  • 分子類別
  • 各作用機制

開發中產品的最新趨勢

暫停開發的產品

中止開發的產品

  • 中止開發的產品簡介
    • arumorekisanto
    • Clazosentan
    • palosuran
    • setipiprant

企業的聲明

公司所在地及子公司

  • 總公司
  • 其他的公司所在地和子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08006CDB

Summary

Global Markets Direct's, 'Actelion Ltd - Product Pipeline Review - 2016', provides an overview of the Actelion Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Actelion Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Actelion Ltd
  • The report provides overview of Actelion Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Actelion Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Actelion Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Actelion Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Actelion Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Actelion Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Actelion Ltd Snapshot
    • Actelion Ltd Overview
    • Key Information
    • Key Facts
  • Actelion Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Actelion Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Actelion Ltd - Pipeline Products Glance
    • Actelion Ltd - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Actelion Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Actelion Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Actelion Ltd - Drug Profiles
    • mechlorethamine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selexipag
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cadazolid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • macitentan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ponesimod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • miglustat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clazosentan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cenerimod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-082
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACT-451840
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACT-541468
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lucerastat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Neurological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Cardiovascular Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-080
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Bacterial Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize Endothelin A Receptor for Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit DNA Ligase for Staphylococcal Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Actelion Ltd - Pipeline Analysis
    • Actelion Ltd - Pipeline Products by Target
    • Actelion Ltd - Pipeline Products by Route of Administration
    • Actelion Ltd - Pipeline Products by Molecule Type
    • Actelion Ltd - Pipeline Products by Mechanism of Action
  • Actelion Ltd - Recent Pipeline Updates
  • Actelion Ltd - Dormant Projects
  • Actelion Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • almorexant
      • selexipag
  • Actelion Ltd - Company Statement
  • Actelion Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Actelion Ltd, Key Information
  • Actelion Ltd, Key Facts
  • Actelion Ltd - Pipeline by Indication, 2016
  • Actelion Ltd - Pipeline by Stage of Development, 2016
  • Actelion Ltd - Monotherapy Products in Pipeline, 2016
  • Actelion Ltd - Partnered Products in Pipeline, 2016
  • Actelion Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Actelion Ltd - Out-Licensed Products in Pipeline, 2016
  • Actelion Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Actelion Ltd - Pre-Registration, 2016
  • Actelion Ltd - Phase III, 2016
  • Actelion Ltd - Phase II, 2016
  • Actelion Ltd - Phase I, 2016
  • Actelion Ltd - Preclinical, 2016
  • Actelion Ltd - Discovery, 2016
  • Actelion Ltd - Pipeline by Target, 2016
  • Actelion Ltd - Pipeline by Route of Administration, 2016
  • Actelion Ltd - Pipeline by Molecule Type, 2016
  • Actelion Ltd - Pipeline Products by Mechanism of Action, 2016
  • Actelion Ltd - Recent Pipeline Updates, 2016
  • Actelion Ltd - Dormant Developmental Projects,2016
  • Actelion Ltd - Discontinued Pipeline Products, 2016
  • Actelion Ltd, Subsidiaries

List of Figures

  • Actelion Ltd - Pipeline by Top 10 Indication, 2016
  • Actelion Ltd - Pipeline by Stage of Development, 2016
  • Actelion Ltd - Monotherapy Products in Pipeline, 2016
  • Actelion Ltd - Partnered Products in Pipeline, 2016
  • Actelion Ltd - Pipeline by Top 10 Target, 2016
  • Actelion Ltd - Pipeline by Route of Administration, 2016
  • Actelion Ltd - Pipeline by Molecule Type, 2016
  • Actelion Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top